Creating a Flexible Office Space Post-Pandemic

With companies preparing to bring workers back to the office after a two-year-long global pandemic, what that environment looks like is the essential question people are asking.

Bryce Stuckenschneider, President & CEO at Loftwall, says the most important advice he can offer companies trying to figure out their post-pandemic office space requirements is to be willing to change. Flexible office space can adapt to the needs now and accommodate changes down the road.

“Be prepared to throw your plans out the window, to change, to listen to your employees, to listen to workplace strategists, and ‘what’s next’ because those are the companies that people are going to want to stay at,” said Stuckenschneider.

There is an intense battle for talent now, and companies willing to listen to their employees’ needs and offer a flexible office space could hold the advantage over those who do not. People may be momentarily excited to come together in an office environment, but does that open floor plan workspace, so popular before 2020, give employees the same ability to get their focus-work done, as they became accustomed to working from home? It’s a factor companies have no choice but to consider.

Loftwall products provide flexibility and adaptability to the workspace without all construction costs. And a little bit of privacy can give a whole lot of focus—focus employees returning to the office desire and need. Change is constant, and there is no reason why the office can’t be ready to meet those changes head-on. For more industry insights, stay tuned to MarketScale.com.

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More